Molecular characterization of endometrial cancer: A correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis

International Journal of Gynecological Pathology

Volumn 31, Issue 3, 2012, Pages 195-205

  Peterson, Lisa M ^a   Kipp, Benjamin R ^a   Halling, Kevin C ^a   Kerr, Sarah E ^a   Smith, David I ^a   Distad, Tammy J ^a   Clayton, Amy C ^a   Medeiros, Fabiola ^a  

^a MAYO CLINIC   (United States)

Author keywords

Carcinosarcoma; Clear cell; Endometrioid; Sequencing; Serous

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; AGED; ARTICLE; CORRELATIONAL STUDY; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; COHORT STUDIES; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYDROLASES; METHYLATION; MICROSATELLITE INSTABILITY; MUTATION; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOTRANSFERASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862541350     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318231fc51     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology 2007;39:72-87.
3. Boruban MC, Altundag K, Kilic GS, et al. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev 2008;17:133-8. (Pubitemid 351301624)
4. Levan K, Partheen K, Osterberg L, et al. Chromosomal alterations in 98 endometrioid adenocarcinomas analyzed with comparative genomic hybridization. Cytogenet Genome Res 2006;115:16-22. (Pubitemid 44401347)
5. O'Toole SA, Dunn E, Sheppard BL, et al. Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays. Int J Gynecol Cancer 2006;16:834-42.
6. Kanaya T, Kyo S, Maida Y, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 2003;22:2352-60. (Pubitemid 36566790)
7. Burks RT, Kessis TD, Cho KR, et al. Microsatellite instability in endometrial carcinoma. Oncogene 1994;9:1163-6. (Pubitemid 24095025)
8. Catasus L, Machin P, Matias-Guiu X, et al. Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998;29:1160-4. (Pubitemid 28467540)
9. Catasus L, Gallardo A, Cuatrecasas M, et al. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 2008;21:131-9. (Pubitemid 351172164)
10. Athanassiadou P, Athanassiades P, Grapsa D, et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int J Gynecol Cancer 2007;17:697-704. (Pubitemid 46744009)
11. Kang S, Seo SS, Chang HJ, et al. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma. Int J Gynecol Cancer 2008;18:1339-43.
12. Feng YZ, Shiozawa T, Miyamoto T, et al. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res 2005;11:6133-8. (Pubitemid 41262939)
13. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-91. (Pubitemid 46630943)
14. Lax SF. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 2007;39:46-54.
15. Llobet D, Pallares J, Yeramian A, et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 2009;62:777-85.
16. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2011;2010:162363.
17. Mackay HJ, Gallinger S, Tsao MS, et al. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Cancer 2010;46:1365-73.
18. Black D, Soslow RA, Levine DA, et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 2006;24:1745-53. (Pubitemid 46622146)
19. Karamurzin Y, Rutgers JK. DNA mismatch repair deficiency in endometrial carcinoma. Int J Gynecol Pathol 2009;28:239-55.
20. Hayes MP, Ellenson LH. Molecular alterations in uterine serous carcinoma. Gynecol Oncol 2010;116:286-9.
21. Salvesen HB, MacDonald N, Ryan A, et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 2000;6:3607-13.
22. Doll A, Abal M, Rigau M, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 2008;108:221-9. (Pubitemid 351179637)
23. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998;58:3254-8. (Pubitemid 28371061)
24. Dedes KJ, Wetterskog D, Ashworth A, et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011;8:261-71.
25. Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol 2009;113:370-3.
26. Rudd ML, Price JC, Fogoros S, et al. A unique spectrum of somatic PIK3CA (p110a) mutations within primary endometrial carcinomas. Clin Cancer Res 2011;17:1331-40.
27. Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-RAS alterations. Hum Pathol 2006;37:1465-72. (Pubitemid 44584324)
28. Konopka B, Janiec-Jankowska A, Kwiatkowska E, et al. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. Hum Pathol 28 Apr 2011. [Epub ahead of print].
29. Ikeda T, Yoshinaga K, Suzuki A, et al. Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer. Oncol Rep 2000;7:567-70.
30. Soong R, Robbins PD, Dix BR, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996;27:1050-5. (Pubitemid 26347060)
31. Darvishian FHA, Thaler HT, Bhargava R, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 2004;28:1568-78. (Pubitemid 39564961)
32. Halperin RZS, Habler L, Hadas E, et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of the endometrium. Eur J Gynaecol Oncol 2001;22:122-6. (Pubitemid 32963063)
33. Zheng W, Xiang L, Fadare O, et al. A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol 2011; 35:e1-e14.